Skip to main content

Table 1 Characteristics of the subjects in this study

From: Is greater generic competition also linked to lower drug prices in South Korea?

Variables

All

Duopoly

(2)

Low-competition

(3–25)

Medium-

Competition

(26–75)

High-competition

(76-)

p-value

N = 986

305

554

88

39

Price variance

 

 Mean

0.1167

0.0683

0.1160

0.2268

0.2566

<  0.0001

 Median

0.0714

0.0130

0.0774

0.2004

0.2286

 SD

0.1416

0.1000

0.1366

0.1782

0.1693

ATC

 

 1 (J/L)

168

58

97

11

2

<  0.0001

 2 (A/B/C)

302

100

140

41

21

 3 (M/N)

239

57

148

24

10

 4 (Others)

277

90

169

12

6

Route

 

 Oral

635

156

354

86

39

<  0.0001

 Injection

206

103

101

2

 Others

145

46

99

Year

 

 Mean

2007

2008

2007

2006

2005

0.0001

 Median

2006

2007

2006

2006

2005

 SD

5.3662

5.2816

5.5529

4.5851

3.8231

Types

 

 Biologics

50

28

9

9

4

<  0.0001

 Chemicals

936

277

545

79

35

New drug application

 Yes

154

34

96

13

11

0.0142

 No

832

271

458

75

28

Manufacturers

 Domestic

623

187

372

49

15

0.0008

 Overseas

363

118

182

39

24

Price

 I (<  103 KRW)

502

120

283

67

32

<  0.0001

 II (103 ≤ <  104)

269

86

159

17

7

 III (104 ≤ <  105)

154

67

83

4

 IV (105 ≤ <  106)

55

26

29

 V (106≤)

6

6